NFKB1 and lung carcinoma: A possible microenvironmental role for TQ-induction of NF-κB activity and ascites following longer periods of treatment is supported by a recent study showing that the proteasome inhibitor, bortezomib, induces pro-inflammatory effects on the tumor microenvironment, particularly macrophages, subsequently promoting tumor progression in a mouse lung cancer model [34].